Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technology

The Alameda-based company, which boasts a new way of using CRISPR technology, plans to rapidly expand the company in the hopes of creating new treatments for a host of unmet diseases.